KidsMD Health Topics

Myasthenia Gravis in Children

  • Overview

    Juvenile myasthenia gravis (JMG) is the childhood form of myasthenia gravis (MG), and is an autoimmune disease in which a child’s body produces antibodies that attack the acetylcholine receptor and sometimes other proteins at the neuromuscular junction. Acetylcholine is a neurotransmitter that plays a key role in muscle contractions. Not having enough receptor sites for acetylcholine causes a child’s muscles to weaken over time.

    Here’s what you need to know about JMG:

    • JMG should not be confused with congenital myasthenicsyndrome or neonatal myasthenia gravis.  Congenital myasthenic syndrome is a similar but different disease of the neuromuscular junction that is genetic rather than autoimmune in origin. Neonatal myasthenia gravis is a transient (temporary) condition in infants born to mothers with symptomatic or subclinical myasthenia gravis. However, treatment is important because these infants may be quite ill for several weeks.
    • In post-pubertal patients, females are more likely to have JMG than males. In pre-pubertal patients, JMG affects both genders equally.
    • Although JMG can affect people of any age, the disease is relatively rare in children.
    • JMG causes a child’s muscles, especially his eyes, mouth, throat and limbs, to weaken after periods of activity. The weakness usually subsides after a period of rest.
    • Most children with JMG experience symptoms on and off, but the degree of muscle weakness can fluctuate in severity during the “on” times. 
    • In some cases, JMG may be a life threatening condition. However, most people with the disease improve over time if they receive effective treatment.

     

    How Children’s Hospital Boston approaches JMG:

    Since 1977, thousands of children have been successfully diagnosed and treated at the Neuromuscular Program where they are evaluated and treated by a team of world-renowned experts in child neurology, orthopedics and genetics.

    The Department of Ophthalmology and the Ophthalmology Program at Children’s also uses both medical and surgical approaches to treat a wide range of eye conditions caused by neurological disorders such as myasthenia gravis. We use the most advanced diagnostic and treatment methods available and incorporate minimally invasive techniques whenever possible.

    Our teams will work together with your family to develop treatment plans that meet your child's unique needs and provide him with the best possible quality of life.

    Myasthenia gravis: Reviewed by Peter Kang, MD © Children’s Hospital Boston, 2011

Request an Appointment

If this is a medical emergency, please dial 9-1-1. This form should not be used in an emergency.

Patient Information
Date of Birth:
Contact Information
Appointment Details
Send RequestIf you do not see the specialty you are looking for, please call us at: 617-355-6000.International visitors should call International Health Services at +1-617-355-5209.
Please complete all required fields

This department is currently not accepting appointment requests online. Please call us at: 617-355-6000. International +1-617-355-6000.

This department is currently not accepting appointment requests online. Please call us at: 617-355-6000. International +1-617-355-6000.

Thank you.

Your request has been successfully submitted

You will be contacted within 1 business day.

If you have questions or would like more information, please call:

617-355-6000 +1-617-355-6000
close
Find a Doctor
Search by Clinician's Last Name or Specialty:
Select by Location:
Search by First Letter of Clinician's Last Name: *ABCDEFGHIJKLMNOPQRSTUVWXYZ
BrowseSearch
Condition & Treatments
Search for a Condition or Treatment:
Show Items Starting With: *ABCDEFGHIJKLMNOPQRSTUVWXYZ
View allSearch
Locations

Contact the Neuromuscular Program

  • 1-617-355-8235
The future of pediatrics will be forged by thinking differently, breaking paradigms and joining together in a shared vision of tackling the toughest challenges before us.”
- Sandra L. Fenwick, President and CEO
Close